- Abstract
- Core Tip
- Full Article (PDF)
- Full Article with Cover (PDF)
- Full Article (XML)
- Full Article (HTML)
- Audio
- PubMed Central
- PubMed
- CrossRef
- Google Scholar
- Similar Articles (735)
- Timeline of Article Publication (0)
- Authors Evaluation (1)
- Article Quality Tracking (0)
- Reference Citation Analysis (1)
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7640)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Aug 7, 2023 (publication date) through Apr 15, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Wang LF, Chen PR, He SK, Duan SH, Zhang Y. Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review. World J Gastroenterol 2023; 29(29): 4481-4498 [PMID: 37621757 DOI: 10.3748/wjg.v29.i29.4481] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5190/full/v29/i29/4481.htm |
| Number | Citing Articles |
| 1 |
Julia López De-La-Cruz, Fernando Gomollón, Javier Louro, Juan López Pérez, María Mercedes Nocito Colon, Beatriz Gallego Llera, Sandra García-Mateo, Samuel J Martínez-Domínguez, María Concepción Aso Gonzalvo, Carla J Gargallo-Puyuelo. Impact of HLADQA1*05 and HLADQA1*03 on Safety and Loss of Response to Anti-Tumor Necrosis Factor in Patients With Inflammatory Bowel Disease. Journal of Crohn's and Colitis 2024; doi: 10.1093/ecco-jcc/jjae178
|
| 2 |
Ahmad K. Al-Jalehawi, Samer Imad Mohammed. Clinical use of tumor necrosis factor-alpha inhibitors in Iraq: a review of their documented efficacy, safety, and associated genetics. Review of Clinical Pharmacology and Pharmacokinetics - International Edition 2024; 38(3): 335 doi: 10.61873/SEZR6390
|
| 3 |
Cody S Howe, Marina Chulkina, Ryan Syrcle, Christina McAninch, Steven McAninch, Irina V Pinchuk, Ellen J Beswick. MK2 Inhibition in CD4+ T Cells Protects Against IFNγ and IL-17A, Chronic Inflammation, and Fibrosis in Inflammatory Bowel Disease Models. Inflammatory Bowel Diseases 2025; doi: 10.1093/ibd/izaf026
|
| 4 |
Moushira Zaki, Hisham A. Orban, Marwa Mahmoud, Eman R. Youness, Hoda F. Booles, Wagdy K. B. Khalil, Wafaa Wafy, Kamal A. El-Atrebi, Khaled Hamed, Hala T. El-Bassyouni. Evaluation of adropin, fibroblast growth factor-1 (FGF-1), and Toll-like receptor-1 (TLR1) biomarkers in patients with inflammatory bowel disease: gene expression of TNF-α as a marker of disease severity. Egyptian Journal of Medical Human Genetics 2024; 25(1) doi: 10.1186/s43042-024-00533-2
|
| 5 |
José Luis Rueda García, Cristina Suárez-Ferrer, Clara Amiama Roig, Laura García Ramírez, Cristina García Rojas, Eduardo Martín-Arranz, Joaquín Poza Cordón, María Sánchez Azofra, Jesús Noci, Cristina Cubillo García, María Dolores Martín-Arranz. Association of early therapeutic drug monitoring of adalimumab with biologic remission and drug survival in Crohn’s Disease. Therapeutic Advances in Gastroenterology 2025; 18 doi: 10.1177/17562848251324226
|
| 6 |
Yue Yang, Kan-Zuo Fu, Gu Pan. Role of Oncostatin M in the prognosis of inflammatory bowel disease: A meta-analysis. World Journal of Gastrointestinal Surgery 2024; 16(1): 228-238 doi: 10.4240/wjgs.v16.i1.228
Abstract(511) |
Core Tip(521) |
Full Article(HTML)(1546)
|
Full Article with Cover (PDF)-3312K(73)
|
Full Article (Word)-1272K(15)
|
Audio-338K(8)
|
Peer-Review Report-177K(57)
|
Answering Reviewers-115K(53)
|
Supplementary Material-213K(56)
|
Full Article (PDF)-3033K(103)
|
Full Article (XML)-117K(53)
|
Times Cited (7)
|
Total Visits (5399)
|
Open
|
| 7 |
Ji-Eun Na, Yong-Eun Park, Jong-Ha Park, Tae-Oh Kim, Jong-Yoon Lee, Jong-Hoon Lee, Su-Bum Park, Seung-Bum Lee, Seung-Min Hong. Efficacy of Second-Line Biological Therapies in Moderate to Severe Ulcerative Colitis Patients with Prior Failure of Anti-Tumor Necrosis Factor Therapy: A Multi-Center Study. Journal of Personalized Medicine 2024; 14(10): 1066 doi: 10.3390/jpm14101066
|
| 8 |
Dongyuan Zheng, Qinke Xu, Jin Wu, Zhouyue Gu, Jieya Chen, Yingchao Liu. Prevalence and bidirectional association between primary sclerosing cholangitis and Crohn's disease: A systematic review and meta-analysis. Gastroenterología y Hepatología 2025; : 502346 doi: 10.1016/j.gastrohep.2025.502346
|
| 9 |
Nikil Vootukuru, Abhinav Vasudevan. Approach to loss of response to advanced therapies in inflammatory bowel disease. World Journal of Gastroenterology 2024; 30(22): 2902-2919 doi: 10.3748/wjg.v30.i22.2902
|
| 10 |
Shi-Yan Zhang. Navigating new horizons in inflammatory bowel disease: Integrative approaches and innovations. World Journal of Gastroenterology 2024; 30(41): 4411-4416 doi: 10.3748/wjg.v30.i41.4411
|